Targeting VEGF in Cancer Therapy
Authors:
- 28 February 2006
- journal article
- review article
- Published by Elsevier in Current Problems in Cancer
- Vol. 30 (1) , 7-32
Abstract
No abstract availableThis publication has 76 references indexed in Scilit:
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- The vascular endothelial growth factor family and its receptorsHematology/Oncology Clinics of North America, 2004
- Use of Soluble Recombinant Decoy Receptor Vascular Endothelial Growth Factor Trap (VEGF Trap) to Inhibit Vascular Endothelial Growth Factor ActivityClinical Colorectal Cancer, 2004
- Constitutive and inducible expression and regulation of vascular endothelial growth factorCytokine & Growth Factor Reviews, 2004
- Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignanciesJournal of Clinical Oncology, 2004
- Vascular Endothelial Growth Factor as a Target for Anticancer TherapyThe Oncologist, 2004
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- Resistance to Anti-VEGF AgentsCurrent Pharmaceutical Design, 2004
- VEGF-Trap: A VEGF blocker with potent antitumor effectsProceedings of the National Academy of Sciences, 2002
- Purification and Characterization of a Naturally Occurring Vascular Endothelial Growth Factor · Placenta Growth Factor HeterodimerJournal of Biological Chemistry, 1995